Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00339599 · ClinicalTrials.gov registry record
Genetic Predictors of Cardiovascular Disease
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 2,306
- Enrollment target
NCT00339599: Completed study, sponsored by National Cancer Institute (NCI).
NCT00339599 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 2,306 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00339599 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 2,306 participants
- Enrollment target
Study Summary
This study, conducted in collaboration with the Johns Hopkins University School of Medicine, will explore the genetic influences on susceptibility to atherosclerotic cardiovascular disease (ASCVD). Atherosclerosis is a chronic narrowing of the arteries caused by an incremental buildup of fatty substances on the linings of walls of arteries. This study will examine the role of genes related to the inflammatory process on the incidence of ASCVD and on levels of chemokines (proteins involved in inflammation). DNA samples, chemokines levels and relevant clinical data from patients enrolled in Johns Hopkins's sibling and family heart studies are analyzed for specific gene markers. The studies include: Nurse Model in Black Families at Risk for Heart Disease; Genotypic Determinants of Aspirin Response in High Risk Families; and Coronary Disease Detection by Thallium SPECT and Fast CT. All of the enrolled patients have consented to have their DNA used for testing of genetic factors that may predict cardiovascular disease and do not contain patient identifier information.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,306 participants |
| Start Date | 2005-09-20 |
| Est. Completion | 2015-08-03 |
What the finished NCT00339599 record still lists
NCT00339599 is an observational study that tracks outcomes without assigning an intervention. Its 2,306 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT00339599 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00339599 about?
NCT00339599 is a clinical study titled "Genetic Predictors of Cardiovascular Disease". This study, conducted in collaboration with the Johns Hopkins University School of Medicine, will explore the genetic influences on susceptibility to atherosclerotic cardiovascular disease (ASCVD). Atherosclerosis is a chronic narrowing of the arteries caused by an incremental buildup of fatty subst...
What is the current status of trial NCT00339599?
This trial is currently completed. The enrollment target is 2,306 participants. The study started on 2005-09-20. Estimated completion is 2015-08-03.
Who is sponsoring clinical trial NCT00339599?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05485961 · 2,310 participants · Phase 2
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis
- NCT04124120 · 2,300 participants · NA
Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women
- NCT05237258 · 2,300 participants · NA
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
- NCT05732623 · 2,300 participants
Exogenous and Endogenous Risk Factors for Early-onset Colorectal Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI